TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 2.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 2.58nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 2.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 2.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3.30nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3.30nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3.35nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3.45nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3.55nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3.90nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3.96nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.04nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.23nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.38nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.49nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.52nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.61nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.70nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.70nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.70nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.70nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.80nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.80nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.91nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 5nMAssay Description:Inhibition of Bub1 kinase (unknown origin) by TR-FRET kinase assayMore data for this Ligand-Target Pair